Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

A method for identification of HIV gp140 binding memory B cells in human blood.

Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, Seaman MS, Mascola JR, Wyatt RT, Wardemann H, Nussenzweig MC.

J Immunol Methods. 2009 Apr 15;343(2):65-7. doi: 10.1016/j.jim.2008.11.012. Epub 2008 Dec 25.

2.

Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.

Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, Velinzon K, Seaman MS, Nussenzweig MC.

PLoS One. 2011;6(9):e24078. doi: 10.1371/journal.pone.0024078. Epub 2011 Sep 8.

3.

Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.

Quinnan GV Jr, Onabajo O, Zhang P, Yan L, Mattapallil JJ, Zhang Z, Dong M, Lu M, Montefiori D, LaBranche C, Broder CC.

PLoS One. 2014 May 20;9(5):e98060. doi: 10.1371/journal.pone.0098060. eCollection 2014.

4.

Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals.

Montezuma-Rusca JM, Moir S, Kardava L, Buckner CM, Louie A, Kim LJ, Santich BH, Wang W, Fankuchen OR, Diaz G, Daub JR, Rosenzweig SD, Chun TW, Li Y, Braylan RC, Calvo KR, Fauci AS.

J Immunol. 2015 Mar 15;194(6):2561-8. doi: 10.4049/jimmunol.1402424. Epub 2015 Feb 13.

5.

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.

Stamatos NM, Mascola JR, Kalyanaraman VS, Louder MK, Frampton LM, Birx DL, VanCott TC.

J Virol. 1998 Dec;72(12):9656-67.

6.

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M.

J Virol. 2009 Jan;83(1):188-99. doi: 10.1128/JVI.01583-08. Epub 2008 Oct 15.

7.
8.

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Richardson TM Jr, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.

J Virol. 1996 Feb;70(2):753-62.

9.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

10.

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.

Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC, Berkhout B, Binley JM, Moore JP, Sanders RW.

J Virol. 2012 Mar;86(5):2488-500. doi: 10.1128/JVI.06259-11. Epub 2011 Dec 28.

11.

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX.

AIDS Res Hum Retroviruses. 2005 Jan;21(1):58-67.

PMID:
15665645
12.

Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.

Zhang MY, Yuan T, Li J, Rosa Borges A, Watkins JD, Guenaga J, Yang Z, Wang Y, Wilson R, Li Y, Polonis VR, Pincus SH, Ruprecht RM, Dimitrov DS.

PLoS One. 2012;7(9):e44241. doi: 10.1371/journal.pone.0044241. Epub 2012 Sep 10.

13.

[Identification of Env-specific monoclonal antibodies from Chinese HIV-1 infected person by B cell activation and RT-PCR cloning].

Wang HM, Xu K, Yu SQ, Ding LL, Luo HY, Flinko R, Lewis GK, Feng X, Shao JR, Guan YJ, Zeng Y.

Bing Du Xue Bao. 2012 Jun;28(4):358-65. Chinese.

PMID:
22978159
14.

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, Lifson J, Moss B.

J Virol. 2001 Jan;75(2):645-53.

15.

HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.

Bower JF, Li Y, Wyatt R, Ross TM.

Vaccine. 2006 Jun 29;24(26):5442-51. Epub 2006 Apr 3.

PMID:
16621193
16.

Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization.

Zhang PF, Cham F, Dong M, Choudhary A, Bouma P, Zhang Z, Shao Y, Feng YR, Wang L, Mathy N, Voss G, Broder CC, Quinnan GV Jr.

Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10193-8. Epub 2007 May 31.

17.

Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.

Dey AK, Burke B, Sun Y, Sirokman K, Nandi A, Hartog K, Lian Y, Geonnotti AR, Montefiori D, Franti M, Martin G, Carfi A, Kessler P, Martin L, Srivastava IK, Barnett SW.

PLoS One. 2012;7(1):e30233. doi: 10.1371/journal.pone.0030233. Epub 2012 Jan 24.

18.

Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.

Ma BJ, Alam SM, Go EP, Lu X, Desaire H, Tomaras GD, Bowman C, Sutherland LL, Scearce RM, Santra S, Letvin NL, Kepler TB, Liao HX, Haynes BF.

PLoS Pathog. 2011 Sep;7(9):e1002200. doi: 10.1371/journal.ppat.1002200. Epub 2011 Sep 1.

20.

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8. Epub 2002 May 7.

Supplemental Content

Support Center